| PRECIGEN INC. |
| USA |
| Gesundheit |
| US74017N1054 / A2PZG1 |
| I5X (Frankfurt) / PGEN (NASDAQ) |
| FRA:I5X, ETR:I5X, I5X:GR, NASDAQ:PGEN |
| - |
| https://precigen.com/ |
|
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company oper..
>Volltext.. |
| 1254.4 Mio. EUR |
| 1254.77 Mio. EUR |
| 8.27 Mio. EUR |
| -88.31 Mio. EUR |
| -214.06 Mio. EUR |
| -1.2 EUR |
| 83.94 Mio. EUR |
| 25.82 Mio. EUR |
| - |
| 2.62 |
| 117.47% |
| -75% |
| - |
| - |
| - |
| - |
| PRECIGEN |
| 14.05.26 |
|